Yunnan Baiyao reports CNY 21.88 billion first-half revenue: what it means for Yunnan Baiyao stock

Published on 10/25/2026 at 01:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 3.00 percent to CNY 21.88 billion. Orient Securities cut its target to CNY 57.00 for Yunnan Baiyao stock.

Revenue and analyst expectations

First-half revenue reached CNY 21.88 billion in 2026, up 3.00 percent year over year.
Orient Securities cut its target to CNY 57.00 on September 24, 2026.
Yunnan Baiyao stock stood at CNY 52.40 at 3:04 p.m. CST on October 23, 2026.

Yunnan Baiyao, CNE0000008X7, Illustration mit AI erstellt.

Yunnan Baiyao reported CNY 21.88 billion in first-half 2026 revenue, up 3.00 percent year over year, while its stock last stood at CNY 52.40 on the Shenzhen Stock Exchange on October 23, 2026 at 3:04 p.m. CST. The latest figures leave investors weighing steady sales growth against a lower analyst valuation.

Futunn reported on September 24, 2026, that Orient Securities cut its target for Yunnan Baiyao from CNY 65.78 to CNY 57.00 and retained a Buy rating. The target cut followed the first-half report and reflected lower revenue forecasts for 2026 through 2028.

Revenue growth meets a mixed quarter

The half-year total masks a softer second quarter. Revenue reached CNY 10.28 billion in the second quarter of 2026, down 1.30 percent from the year-earlier quarter, while net income was CNY 1.66 billion, down 2.00 percent. The comparison is important because first-quarter revenue was CNY 11.60 billion, making second-quarter sales CNY 1.32 billion lower sequentially.

El Fondo identifies Yunnan Baiyao as a specialty and generic drug manufacturer with pharmaceutical products, health supplements, medical devices and traditional Chinese medicine ingredients. Its 2025 revenue was CNY 41.19 billion, up 2.88 percent, providing a longer comparison for the first-half 2026 increase.

What does the target cut mean?

The lower target contrasts with several faster-growing product lines. The September 24 analysis cited CNY 3.40 billion in revenue for Qi Xue Kang oral liquid, up 68.10 percent year over year, while the health-products business reported CNY 2.40 billion from anti-sensitivity toothpaste and CNY 2.10 billion from whitening toothpaste. Those figures point to growth pockets, although the same analysis listed weaker terminal demand, slower new-product sales and research delays as risks.

Three dated stock milestones

On August 29, 2026, second-quarter revenue was reported at CNY 10.28 billion and net income at CNY 1.66 billion. On September 24, 2026, Orient Securities lowered its target from CNY 65.78 to CNY 57.00. On October 19, 2026, the stock was reported to have risen 2.09 percent in the Shenzhen session.

Dates and valuation markers

The next substantiated reporting date is not included in the cited company and market materials. As of October 23, 2026, Yunnan Baiyao had a market capitalization of CNY 93.5 billion, while its 52-week range was CNY 46.29 to CNY 58.20. The last price was 10.00 percent below the 52-week high.

Stock stays below its yearly high

For investors, the central tension is measurable: first-half revenue grew 3.00 percent, but second-quarter revenue fell 1.30 percent year over year and the latest analyst target was cut by 13.35 percent from CNY 65.78 to CNY 57.00.

Yunnan Baiyao stock was last at CNY 52.40 on the Shenzhen Stock Exchange on October 23, 2026 at 3:04 p.m. CST.